Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Probucol - Vyrex

Drug Profile

Probucol - Vyrex

Alternative Names: Panavir

Latest Information Update: 03 Jul 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vyrex Corporation
  • Class Antihyperlipidaemics; Phenols
  • Mechanism of Action Antioxidants; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended HIV infections
  • Discontinued Cerebral vasospasm

Most Recent Events

  • 31 Dec 2005 Suspended - Phase-I for HIV infections treatment in USA (PO)
  • 31 Mar 2004 Discontinued - Preclinical for Cerebral vasospasm in USA (PO)
  • 17 Sep 2002 Preclinical data from a media release has been added to the Neurological Disorders and Vascular Disorders pharmacodynamics fields
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top